Relation of Endogenous Testosterone Levels with Cardiometabolic Risk Factors in Hypogonadal Men

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 554-583-Male Reproductive Endocrinology & Case Reports
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-578
Andre B. Araujo*1, Julia F. Martha2, Mario Maggi3, Giulia Rastrelli3, Thomas Hugh Jones4, Teresa M. Curto2 and Raymond C. Rosen2
1New England Research Institutes, Watertown, MA, 2New England Research Institutes, Inc., Watertown, MA, 3AOU Careggi - University of Florence, Florence, Italy, 4Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom
Introduction: Hypogonadism (HG) is a prevalent condition in men with broad health and quality of life consequences. We examined the relation of endogenous testosterone (T) levels with cardiometabolic factors in the Registry of Hypogonadism in Men (RHYME).

Methods: RHYME is a multi-center registry of 999 men with clinically-diagnosed HG (naïve to androgen treatment) from 25 sites in 6 European countries (DE/ES/IT/NL/SE/UK). T was measured in a central laboratory by liquid chromatography-tandem mass spectrometry. Cardiometabolic factors included measured height and weight [used to calculate body mass index (BMI)], waist, and blood pressure [high blood pressure (HBP) defined as SBP≥140 or DBP≥90mmHg]. Hypercholesterolemia, diabetes, and use of anti-hypertensive, lipid-lowering, and anti-diabetic medications were assessed by medical record. Smoking and physical activity were assessed by self-reported questionnaire. Unadjusted associations with T were assessed via Pearson’s correlation coefficient (r) for continuous variables and t-tests for binary categorical variables. Differences in geometric mean T (log-scale) in relation to cardiometabolic factors were assessed via multivariable linear regression models controlling for age, BMI, HG duration, smoking, PA, self-rated health, number of comorbidities, blood draw time, and country.

Results: Mean age and T were 59±10.5y and 9.5±1.6nmol/L, with high rates of obesity (44%), HBP (50%), hypercholesterolemia (31%), and diabetes (29%). There were significant differences in T by country (range: UK, 9.9nmol/L; DE, 11.8nmol/L). T levels were significantly correlated with BMI (r=-0.23) and waist (r=-0.20) but not SBP or DBP. Mean T levels were unrelated to smoking, physical activity, HBP, hypercholesterolemia, diabetes, or use of medications to treat these conditions in unadjusted or adjusted analyses. More men with lower T were taking anti-hypertensives and lipid-lowering agents, but the relation between T and HBP or hypercholesterolemia was not different in men taking or not taking these medications. BMI did not modify associations between other cardiometabolic factors and T.

Conclusions: Among men with diagnosed HG, endogenous T levels are strongly associated with body composition but not other cardiometabolic outcomes. Future analyses will be important to understand directionality of these associations and whether T therapy improves cardiometabolic outcomes in obese men with HG.

Disclosure: ABA: Consultant, Eli Lilly & Company, Principal Investigator, GlaxoSmithKline, Principal Investigator, Abbott Laboratories. MM: Consultant, Bayer, Inc., Consultant, Eli Lilly & Company. THJ: Consultant, Bayer Healthcare, Researcher, Bayer Healthcare, Speaker, Bayer Healthcare, Consultant, Eli Lilly & Company, Consultant, Pro Strakan, Researcher, Pro Strakan, Speaker, Pro Strakan, Consultant, Merck, Consultant, Clarus. RCR: Principal Investigator, Bayer Health Care, Consultant, Eli Lilly & Company, Consultant, Ferring Pharmaceuticals. Nothing to Disclose: JFM, GR, TMC

*Please take note of The Endocrine Society's News Embargo Policy at

Sources of Research Support: Bayer Pharma AG